PHARMA HOLDINGS AS
🇳🇴Norway
Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus
Phase 2
Completed
- Conditions
- Nasal Decolonization of Staphylococcus Aureus
- Interventions
- Drug: Vehicle gel, 4 + 4 applications or 4 + 2 applications
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 27
- Registration Number
- NCT05889351
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 60
- Registration Number
- NCT04854928
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus
Phase 1
Completed
- Conditions
- Nasal Decolonization of Staphylococcus Aureus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 15
- Registration Number
- NCT04767321
- Locations
- 🇸🇪
ClinSmart Sweden AB, Uppsala, Sweden
LTX-109 as Treatment for Hidradenitis Suppurativa
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Pharma Holdings AS
- Target Recruit Count
- 11
- Registration Number
- NCT04756336
- Locations
- 🇳🇴
University Hospital of North Norway, Tromsø, Norway
© Copyright 2025. All Rights Reserved by MedPath